Table 3.
Effect sizes and mean (and SD) endpoint change in SOPS and MADRS severity scores (LOCF).
| SOPS total | SOPS positive | SOPS negative | SOPS disorganized | SOPS general | MADRS total | |
|---|---|---|---|---|---|---|
| Open-label glycine (n= 10) | ||||||
| 8w Change | –15.3 (11.0)* | –5.7 (5.2)* | –3.0 (4.1)* | –3.1 (3.0)* | –3.5 (3.1)* | –2.1 (4.8)a* |
| Within group effect size | –1.39 | –1.10 | –0.74 | –1.05 | –1.12 | –0.44 |
| Double-blind active glycine (n=4) | ||||||
| 8w Change | –5.8 (8.1) | –2.3 (2.8) | –1.5 (2.5) | –0.3 (1.7) | –1.8 (2.4) | –5.8 (4.0) |
| Within group effect size | –0.71 | –0.82 | –0.60 | –0.15 | –0.74 | −1.43 |
| Double-blind placebo (n=4) | ||||||
| 8w Change | 4.5 (9.7) | 2.0 (4.7) | 0.3 (1.9) | 1.0 (2.0) | 1.3 (1.3) | 3.3 (4.9)b |
| Within group effect size | 0.46 | 0.43 | 0.13 | 0.50 | 0.99 | 0.68 |
| Double-blind glycine vs. placebo | ||||||
| Between groups effect size | –1.15 | –1.11 | –0.79 | –0.67 | –1.58 | –2.06* |
a
n=8.
b
n=3.
*
p<0.05 by paired or Student's t-test as appropriate.